154 related articles for article (PubMed ID: 38399423)
1. Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor.
Almasoudi HH; Mashraqi MM; Alshamrani SA; Alharthi AA; Alsalmi O; Nahari MH; Al-Mansour FSH; Alhazmi AYM
Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399423
[TBL] [Abstract][Full Text] [Related]
2. Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer: a structure-based in-silico approach.
Alsaiari AA; Gharib AF; Bakhuraysah MM; Alrehaili AA; Algethami SM; Alsaif HA; Al Harthi N; Hakami MA
Med Oncol; 2024 Apr; 41(5):117. PubMed ID: 38630325
[TBL] [Abstract][Full Text] [Related]
3. Structure-based multitargeted docking screening, pharmacokinetics, DFT, and dynamics simulation studies reveal mitoglitazone as a potent inhibitor of cellular survival and stress response proteins of lung cancer.
Binshaya AS; Alkahtani OS; Aldakheel FM; Hjazi A; Almasoudi HH
Med Oncol; 2024 Mar; 41(5):101. PubMed ID: 38546811
[TBL] [Abstract][Full Text] [Related]
4. Delineating Pixantrone Maleate's adroit activity against cervical cancer proteins through multitargeted docking-based MM\GBSA, QM-DFT and MD simulation.
Almasoudi HH; Nahari MH; Alhazmi AYM; Almasabi SHA; Al-Mansour FSH; Hakami MA
PLoS One; 2023; 18(12):e0295714. PubMed ID: 38100507
[TBL] [Abstract][Full Text] [Related]
5. Delineated 3-1-BenCarMethInYlPro-Phosphonic Acid's Adroit Activity against Lung Cancer through Multitargeted Docking, MM\GBSA, QM-DFT and Multiscale Simulations.
Hakami MA; Hazazi A; Albloui F; Gharib AF; Alsaeedi FA; Abdulaziz O; Alhazmi AY; Alsaiari AA
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203761
[TBL] [Abstract][Full Text] [Related]
6. Multitargeted inhibitory effect of Mitoxantrone 2HCl on cervical cancer cell cycle regulatory proteins: a multitargeted docking-based MM\GBSA and MD simulation study.
Alshehri MA; Asiri SA; Alzahrani A; Alazragi RS; Alqahtani LS; Alqosaibi AI; Alnamshan MM; Alam Q; Rafeeq MM
Med Oncol; 2023 Oct; 40(11):337. PubMed ID: 37864019
[TBL] [Abstract][Full Text] [Related]
7. Multisampling-based docking reveals Imidazolidinyl urea as a multitargeted inhibitor for lung cancer: an optimisation followed multi-simulation and
Ahmad S; Singh V; Gautam HK; Raza K
J Biomol Struct Dyn; 2024 Mar; 42(5):2494-2511. PubMed ID: 37154501
[TBL] [Abstract][Full Text] [Related]
8. Unveiling the multitargeted repurposing potential of taxifolin (dihydroquercetin) in cervical cancer: an extensive MM\GBSA-based screening, and MD simulation study.
Almasoudi HH; Hakami MA; Alhazmi AY; Makkawi M; Alasmari S; Alghamdi YS; Mashraqi MM
Med Oncol; 2023 Jul; 40(8):218. PubMed ID: 37394519
[TBL] [Abstract][Full Text] [Related]
9. Molecular screening reveals Variolin B as a multitargeted inhibitor of lung cancer: a molecular docking-based fingerprinting and molecular dynamics simulation study.
Almasoudi HH; Mashraqi MM; Alshamrani S; Alsalmi O; Alharthi AA; Gharib AF
J Biomol Struct Dyn; 2024; 42(1):11-21. PubMed ID: 37771142
[TBL] [Abstract][Full Text] [Related]
10. Identification of 5-nitroindazole as a multitargeted inhibitor for CDK and transferase kinase in lung cancer: a multisampling algorithm-based structural study.
Ahmad S; Raza K
Mol Divers; 2023 Apr; ():. PubMed ID: 37058176
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone 2HCl's adroit activity against cervical cancer replication and maintenance proteins: a multitargeted approach.
Hakami MA; Hazazi A; Alsulami MO; Alsaiari AA
J Biomol Struct Dyn; 2024 Mar; ():1-14. PubMed ID: 38517073
[TBL] [Abstract][Full Text] [Related]
12. Variolin B from sea sponge against lung cancer: a multitargeted molecular docking with fingerprinting and molecular dynamics simulation study.
Alsalmi O; Mashraqi MM; Alshamrani S; Almasoudi HH; Alharthi AA; Gharib AF
J Biomol Struct Dyn; 2024 Apr; 42(7):3507-3519. PubMed ID: 37855303
[TBL] [Abstract][Full Text] [Related]
13. Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies.
Yousif FA; Alzain AA; Alraih AM; Ibraheem W
PLoS One; 2023; 18(9):e0291256. PubMed ID: 37682937
[TBL] [Abstract][Full Text] [Related]
14. Unveiling the multitargeted potency of Sodium Danshensu against cervical cancer: a multitargeted docking-based, structural fingerprinting and molecular dynamics simulation study.
Alghamdi S; Baeissa HM; Azhar Kamal M; Rafeeq MM; Al Zahrani A; Maslum AA; Hakeem IJ; Alazragi RS; Alam Q
J Biomol Struct Dyn; 2023 Aug; ():1-13. PubMed ID: 37599470
[TBL] [Abstract][Full Text] [Related]
15. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
[TBL] [Abstract][Full Text] [Related]
16. A drug design strategy based on molecular docking and molecular dynamics simulations applied to development of inhibitor against triple-negative breast cancer by Scutellarein derivatives.
Akash S; Aovi FI; Azad MAK; Kumer A; Chakma U; Islam MR; Mukerjee N; Rahman MM; Bayıl I; Rashid S; Sharma R
PLoS One; 2023; 18(10):e0283271. PubMed ID: 37824496
[TBL] [Abstract][Full Text] [Related]
17.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
18. Identification of small molecule inhibitors of RAD52 for breast cancer therapy: in silico approach.
Kumar M; Dubey R; Kumar Shukla P; Dayal D; Kumar Chaubey K; Tsai LW; Kumar S
J Biomol Struct Dyn; 2024 Jun; 42(9):4605-4618. PubMed ID: 37288783
[TBL] [Abstract][Full Text] [Related]
19. In silico high-throughput virtual screening and molecular dynamics simulation study to identify inhibitor for AdeABC efflux pump of Acinetobacter baumannii.
Verma P; Tiwari M; Tiwari V
J Biomol Struct Dyn; 2018 Apr; 36(5):1182-1194. PubMed ID: 28393677
[TBL] [Abstract][Full Text] [Related]
20. Revolutionizing anti-cancer drug discovery against breast cancer and lung cancer by modification of natural genistein: an advanced computational and drug design approach.
Akash S; Bibi S; Biswas P; Mukerjee N; Khan DA; Hasan MN; Sultana NA; Hosen ME; Jardan YAB; Nafidi HA; Bourhia M
Front Oncol; 2023; 13():1228865. PubMed ID: 37817764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
